5th Lipid Nanoparticles Development Summit Europe

As lipid nanoparticles move beyond COVID-19 vaccines into gene editing, oncology and in vivo cell therapy, the barriers to clinical translation are sharpening, and so is the industry's focus on solving them.

End-to-end LNP development: from early design to clinical application

The 5th Lipid Nanoparticles Development Summit Europe is structured around an end-to-end programme, covering the full development arc from early formulation design through to clinical-stage challenges. The event's stated scope spans the biggest barriers preventing LNPs from reaching their full clinical potential, with participation from leading biotech, pharma and academic experts. Specific tracks and session titles are not detailed in the available source material, but the thematic breadth, gene editing, oncology and in vivo cell therapy, signals a programme relevant across multiple therapeutic modalities.

Which R&D and CMC teams should be tracking this Berlin summit

For formulation scientists, CMC leads and R&D directors working on nucleic acid delivery or next-generation LNP platforms, the summit's cross-disciplinary mix of biotech, pharma and academic voices offers a concentrated read on where the field is moving. The shift from vaccine-only applications into broader therapeutic areas makes this particularly relevant for teams scoping pipeline decisions or technology partnerships ahead of 2027 programmes.

Registration is available via the event website; prospective attendees should confirm availability and deadlines directly with the organiser, Hanson Wade.